The EU emergency authorization for vaccines, in addition to the adjustments for the variants, could also concern the new sera that are already part of the Union strategy but which still need to be approved
It is learned in Brussels.
The European Commission is working on the hypothesis, which however presents legal hurdles.
A first round of the table with the 27 has already been made.
In addition to the Johnson & Johnson vaccine, which could get the go-ahead from the EMA on March 11, the EU program, still to be approved, includes Curevac and Sanofi and two other contracts should be signed with Novavax and Valneva.